WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases

June 27, 2017 at 7:57 am

Journal of Antimicrobial Chemotherapy June 2017 V.72 N.6 P.1696-1703

EDITOR’S CHOICE

Helio S. Sader; Paul R. Rhomberg; Robert K. Flamm; Ronald N. Jones; Mariana Castanheira

Background: Zidebactam is a β-lactam enhancer antibiotic with a dual mechanism of action involving binding to Gram-negative PBP2 and β-lactamase inhibition. Cefepime combined with zidebactam (WCK 5222) is under clinical development for treatment of Gram-negative infections.

Objectives: To evaluate the in vitro activities of cefepime and zidebactam separately and combined at 1:1 and 2:1 ratios when tested against Gram-negative organisms producing the most clinically relevant β-lactamase types.

Methods: β-Lactamase-producing (193) and WT (71) isolates were tested for susceptibility by broth microdilution method against cefepime/zidebactam, cefepime and zidebactam.

Results: Cefepime/zidebactam (1:1) was very active against Enterobacteriaceae producing CTX-M-15 (21; MIC50/90 0.25/1 mg/L), SHV (20; MIC50/90 0.12/0.25 mg/L), other ESBLs (20, including GES-18, OXA-1/30 and OXY-, PER-, TEM- and VEB-like; MIC50/90 0.25/1 mg/L), plasmidic AmpC (10; MIC50/90 ≤0.06/≤0.06 mg/L), derepressed AmpC (23; MIC50/90 0.12/0.5 mg/L), KPC (35; MIC50/90 0.25/1 mg/L) and metallo-β-lactamases (MBLs; 20 including VIM, IMP and NDM; MIC50/90 0.5/8 mg/L). Cefepime/zidebactam (1:1) was also active against Pseudomonas aeruginosa with overexpression of AmpC (21; MIC50/90 4/8 mg/L) and MBLs [12 (VIM and IMP); MIC50/90 4/8 mg/L]. Zidebactam alone exhibited potent in vitro activity against some Enterobacteriaceae and P. aeruginosa, including β-lactamase-producing strains. Cefepime/zidebactam MIC values were lower than those of each agent tested alone for many β-lactamase-producing strains, indicating synergy. Cefepime/zidebactam showed moderate activity against OXA-23/24/58-producing Acinetobacter baumannii [MIC50/90 32 mg/L (1:1)].

Conclusions: Cefepime/zidebactam showed potent activities against Enterobacteriaceae and P. aeruginosa producing various clinically relevant β-lactamases, including ESBLs, KPCs, AmpC and MBLs for which limited treatment options are currently available.

PDF

https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/72/6/10.1093_jac_dkx050/2/dkx050.pdf?Expires=1498653696&Signature=akCL2mGaLq1JtMTrY92~~SQCIp1ma1GtTYL8KLBM5i5pYRroG-Z4xpV-VgyKnEN2nKGB6aNkrrim9sS3kW7MgQaARimpmatjsbU8KwlYqkxVe2MUUIbj7gcBK6SP82W3hK2nz12jg2xgv309Wvktd~Ph~QYs4vsP5~DHRVo1SyvnMgXTp8ierlT6jsfLFi1qF6P14GHjcDbW5EnGYo0d81dDEtXKO60fnXbjL6X6ZunrHA6jycWCS13cn~gs1GjMqoEEHPKfuYvTaclHAwRv9f2oAjUu~jrnDYUq1skjIt4AlG79UDvZRyBnK82rXf6Z021dBpT0s19BQuqjwFpuVg__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Epidemiología, Metodos diagnosticos, Resistencia bacteriana, Sepsis, Update.

Overexpression of antibiotic resistance genes in hospital effluents over time Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals


Calendar

June 2017
M T W T F S S
« May   Jul »
 1234
567891011
12131415161718
19202122232425
2627282930  

Most Recent Posts


%d bloggers like this: